Home > Insider Trading > Filing (0001735276-23-000044)

Filing Details

Accession Number:: 0001735276-23-000044
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-04-28 17:54:06
Reporting Period:: 2023-04-26

Accepted Time:: 2023-04-28 17:54:06
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178670	Alnylam Pharmaceuticals Inc.	ALNY	Pharmaceutical Preparations (2834)	770602661

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1829252	Pushkal Garg	675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142	Cmo & Evp Dev & Med Affairs	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-04-26	4,294	$0.00	8,639	No	4	A	Direct
Common Stock	Disposition	2023-04-27	151	$193.18	8,488	No	4	S	Direct
Common Stock	Disposition	2023-04-27	700	$193.93	7,788	No	4	S	Direct
Common Stock	Disposition	2023-04-27	779	$194.94	7,009	No	4	S	Direct
Common Stock	Disposition	2023-04-27	80	$195.65	6,929	No	4	S	Direct
Common Stock	Disposition	2023-04-27	129	$197.08	6,800	No	4	S	Direct
Common Stock	Disposition	2023-04-28	204	$195.46	6,596	No	4	S	Direct
Common Stock	Disposition	2023-04-28	103	$196.62	6,493	No	4	S	Direct
Common Stock	Disposition	2023-04-28	715	$198.03	5,778	No	4	S	Direct
Common Stock	Disposition	2023-04-28	385	$199.54	5,393	No	4	S	Direct
Common Stock	Disposition	2023-04-28	955	$200.35	4,438	No	4	S	Direct
Common Stock	Disposition	2023-04-28	93	$201.30	4,345	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	431	Indirect	by Managed Account
Common Stock	250	Indirect	by Trust

Footnotes

On February 23, 2022, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2021 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of human proof-of-concept of an investigational therapeutic directed to an extrahepatic target (central nervous system, or CNS).
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 192.47 to $193.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 193.48 to $194.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 194.49 to $195.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 195.50 to $196.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 194.80 to $195.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 196.31 to $196.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 197.57 to $198.32. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 198.89 to $199.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 199.90 to $200.82. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Reflects shares of ALNY common stock acquired by the reporting person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
Represents shares held in trust, of which the reporting persons spouse is co-trustee. The reporting person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.